At the news
? BULLISHIMPACT 8/10 8-K filed Aug 26, 2026 at 13:33 ET
Revolution Medicines announced FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma on August 26, 2026, based on Phase 3 RASolute 302 data. The oral therapy is now available in the U.S. with a wholesale acquisition cost of $39,800 per 30-day supply. This is a transformative milestone for the company, converting its lead pipeline asset to a commercial product in a large unmet-need indication.
- FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or when multiagent therapy is not an option.
- Approval based on Phase 3 RASolute 302 trial vs. investigator's choice chemotherapy.
- Once-daily oral tablets immediately available for prescribing in the U.S.
- Wholesale acquisition cost is $39,800 for a 30-day supply at the recommended dose.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access